Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEN-221 in SSTR2 Expressing Advanced Cancers
NCT02936323Phase 2Completed
- Sponsor
- Tarveda Therapeutics
- Start
- Dec 2016
- Primary completion
- Jul 2020
- Modality
- Antibody-Drug Conjugates (ADCs), Small Molecules, Peptide-Drug Conjugates
- Countries
- 2
01
Overview
A Phase 2 trial of PEN-221 in Neuroendocrine Neoplasm (NEN), small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC), sponsored by Tarveda Therapeutics. Started Dec 2016; status: completed.
02
Drugs
PEN-221
03
Conditions
Neuroendocrine Neoplasm (NEN)small cell lung cancer (SCLC)large cell neuroendocrine carcinoma (LCNEC)
Beyond the preview
Go deeper on NCT02936323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02936323.